Fingerprint
Dive into the research topics of 'Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study
Carlo Gambacorti-Passerini, Sergey Orlov, Li Zhang, Fadi Braiteh, Huiqiang Huang, Taito Esaki, Keizo Horibe, Jin Seok Ahn, Joseph T. Beck, William Jeffrey Edenfield, Yuankai Shi, Matthew Taylor, Kenji Tamura, Brian A. Van Tine, Shang Ju Wu, Jolanda Paolini, Paulina Selaru, Tae Min Kim
- Section of Medical Oncology
- Bursky Center for Human Immunology & Immunotherapy Programs (CHiiPs)
- Roy and Diana Vagelos Division of Biology & Biomedical Sciences (DBBS)
- Institute of Clinical and Translational Sciences (ICTS)
- Siteman Cancer Center
- DBBS - Molecular Cell Biology
- DBBS - Molecular Genetics and Genomics
- DBBS - Cancer Biology
Research output: Contribution to journal › Article › peer-review
83
Scopus
citations